Johnson & Johnson’s oral drug for a type of skin condition met the main goals of achieving clear or almost clear skin and reduction in patches in a late-stage trial, the drugmaker said on Monday.
Interested in being a guest? Email us at admin@evankirstel.comUnlock the secrets to transforming patient care with our special guest, Dr. Jonathan Kaplan, a pio
Blue Cross Blue Shield of Michigan will instead favor AbbVie’s biosimilar competition next year.
Interested in being a guest? Email us at admin@evankirstel.comDiscover how Nintex is transforming businesses with cutting-edge automation and workflow solutions
A study modelling the impact of melting ice suggests scientists have underestimated the risk that an important ocean current will shut down and cause climate…
Esophageal involvement in scleroderma has many possible manifestations, and long-term use of proton-pump inhibitors can increase the risk of candidiasis.
Nature – Stable epigenetic changes indicate the existence of an obesogenic memory in mouse adipocytes that primes cells for pathological responses in an obesogenic environment…
Drs. Eric Dein and Jonathan Kay discuss the state of biosimilars at the 2024 ACR Convergence meeting in Washington, DC.
Any babywearing enthusiast can likely rattle off a laundry list of reasons they love this parenting practice. But what does the science say? A pediatrician…
Merck is licensing a new cancer drug from a Chinese firm, entering a buzzy field of oncology.
Focus on A-list talent such as Swift and Beyoncé may have reinforced an out-of-touch vision, or maybe celebrity support holds no political power
